Buy Divi's Laboratories; target of Rs 3260: ICICI Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

ICICI Direct's research report on Divi's Laboratories

Mahindra & Mahindra (M&M) reported a relatively healthy operational performance in Q1FY21. Standalone net sales fell 56.6% YoY. Automotive ASPs surprised positively, coming in at Rs 6.9 lakh/unit while ASP for farm equipment segment (FES) i.e. tractor was at Rs 5.1 lakh/unit. Standalone EBITDA in Q1FY21 was at Rs 549 crore with corresponding EBITDA margins at 9.8% (down 261 bps QoQ), primarily tracking a rise in staff costs (percentage of sales basis). Automotive segment posted EBIT loss of Rs 576 crore while EBIT margins in FES expanded strongly by 280 bps QoQ to 20.4%. Consequent standalone PAT for the quarter came in at Rs 112 crore, crimped by lower other income and higher interest costs.

Outlook

We expect sales, EBITDA to grow at 5%, 11.6% CAGR, respectively, in FY20-22E. We continue to like M&M for its strong rural presence and sharpened capital allocation focus, although pace of recovery on automotive side remains a monitorable. We maintain BUY rating on M&M, valuing it at Rs 700/share on SOTP basis (7.5x FY22E EV/EBITDA for base business; 30% holdco discount to its investments).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More